Plus Therapeutics to Present at H.C. Wainwright Conference
AUSTIN, Texas — Plus Therapeutics, Inc. (Nasdaq: PSTV), a groundbreaking clinical-stage pharmaceutical company, is preparing to deliver a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. This esteemed event will take place at the Lotte New York Palace Hotel from September 9 to 11, 2024.
Presentation Details
Marc H. Hedrick, M.D., the President and Chief Executive Officer of Plus Therapeutics, will present the company's overview, which will be available on-demand starting Monday, September 9, at 7:00 AM ET.
Opportunities for Engagement
Management will be open to one-on-one meetings throughout the conference. Those interested can register for the event to secure a chance to meet.
About Plus Therapeutics
Plus Therapeutics is dedicated to developing advanced radiotherapeutics aimed at tackling challenging cancers, especially those impacting the central nervous system. The company leverages state-of-the-art technologies, including image-guided local beta radiation and targeted drug delivery, to significantly enhance patient outcomes. Their primary initiatives focus on treating recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). With a robust leadership team and established partnerships, Plus Therapeutics is strategically positioned for success in the oncology sector. The company operates from key clinical development hubs in Texas, which bolsters their ability to innovate and provide life-saving therapies.
Future Directions
Plus Therapeutics is committed to a proactive research and development strategy, continually seeking new methods to apply their innovative approaches toward meaningful clinical advancements in cancer treatment.
Frequently Asked Questions
What is Plus Therapeutics?
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company that specializes in targeted radiotherapeutics for cancers affecting the central nervous system.
When is Plus Therapeutics presenting at the conference?
They will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.
Who is presenting for Plus Therapeutics?
Marc H. Hedrick, M.D., the President and CEO, will lead the presentation.
What types of cancers does Plus Therapeutics target?
Plus Therapeutics primarily focuses on difficult-to-treat central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases.
How does Plus Therapeutics plan to enhance treatment outcomes?
They utilize a unique combination of image-guided beta radiation and targeted drug delivery to improve the efficacy and precision of cancer treatment.